Company intelligence / Profile preview

Biocerna

Fulton, Maryland, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Other

Overview

Biocerna developed and commercialized non-invasive, accessible, and affordable molecular diagnostic tests—most notably the PGx360™ pharmacogenomic panel—to help physicians select appropriate medications based on patients’ genetic profiles. The company was acquired by Matrix Medical Network in October 2020. No clinical trial results are reported as it is a diagnostics platform.

Therapeutic areas: Other
Modalities: Diagnostic test (genetic panel)Molecular diagnostics (pharmacogenomics)
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Biocerna.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biocerna.

Explore the full profile